Frontier Capital Management Co. LLC Has $24.64 Million Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Frontier Capital Management Co. LLC trimmed its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 5.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 104,718 shares of the biopharmaceutical company's stock after selling 6,513 shares during the quarter. Frontier Capital Management Co. LLC owned approximately 0.08% of Alnylam Pharmaceuticals worth $24,641,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of ALNY. Capital World Investors grew its stake in Alnylam Pharmaceuticals by 0.6% in the 4th quarter. Capital World Investors now owns 16,600,525 shares of the biopharmaceutical company's stock valued at $3,906,284,000 after buying an additional 92,101 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Alnylam Pharmaceuticals by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 12,733,399 shares of the biopharmaceutical company's stock worth $2,996,296,000 after acquiring an additional 98,303 shares during the period. Capital Research Global Investors grew its position in shares of Alnylam Pharmaceuticals by 32.9% in the fourth quarter. Capital Research Global Investors now owns 6,968,513 shares of the biopharmaceutical company's stock valued at $1,639,767,000 after purchasing an additional 1,724,610 shares during the last quarter. Regeneron Pharmaceuticals Inc. acquired a new stake in Alnylam Pharmaceuticals during the 4th quarter worth approximately $1,045,822,000. Finally, T. Rowe Price Investment Management Inc. lifted its holdings in Alnylam Pharmaceuticals by 39.7% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 4,384,449 shares of the biopharmaceutical company's stock worth $1,031,705,000 after purchasing an additional 1,245,195 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

ALNY has been the topic of several recent research reports. JPMorgan Chase & Co. upgraded Alnylam Pharmaceuticals from a "neutral" rating to an "overweight" rating and increased their price objective for the stock from $280.00 to $328.00 in a research report on Monday, March 24th. Citigroup upped their target price on Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the company a "buy" rating in a research report on Friday, March 21st. Chardan Capital increased their price target on shares of Alnylam Pharmaceuticals from $300.00 to $325.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. Needham & Company LLC restated a "buy" rating and set a $320.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Wednesday, April 9th. Finally, UBS Group lifted their target price on Alnylam Pharmaceuticals from $331.00 to $349.00 and gave the company a "buy" rating in a research report on Friday, May 2nd. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and twenty-two have issued a buy rating to the stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus target price of $319.17.

Alnylam Pharmaceuticals Trading Down 2.5%

ALNY stock traded down $6.35 during trading on Friday, hitting $252.00. The company had a trading volume of 656,363 shares, compared to its average volume of 903,611. The stock has a market cap of $32.86 billion, a PE ratio of -116.13 and a beta of 0.17. The business has a 50-day moving average of $250.53 and a 200-day moving average of $253.70. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. Alnylam Pharmaceuticals, Inc. has a one year low of $144.73 and a one year high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.07). The firm had revenue of $594.19 million for the quarter, compared to analysts' expectations of $584.32 million. During the same quarter in the prior year, the business earned ($0.16) EPS. The business's revenue for the quarter was up 20.2% on a year-over-year basis. Research analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CFO Jeffrey V. Poulton sold 967 shares of the stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $255.17, for a total transaction of $246,749.39. Following the transaction, the chief financial officer now directly owns 32,786 shares in the company, valued at approximately $8,366,003.62. This represents a 2.86% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Kevin Joseph Fitzgerald sold 663 shares of Alnylam Pharmaceuticals stock in a transaction on Friday, February 14th. The shares were sold at an average price of $255.21, for a total transaction of $169,204.23. Following the completion of the sale, the executive vice president now owns 14,321 shares of the company's stock, valued at $3,654,862.41. This represents a 4.42% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 7,392 shares of company stock valued at $1,875,627. 1.50% of the stock is currently owned by insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.